Search Within

Anita Kumar

Formats
  1. Meeting Abstract (112)
  2. Journal Article (65)
  3. Review (8)
  4. Book Section (6)
  5. Research Letter (5)
  6. Correspondence (1)
  7. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (198)
  2. Department of Medicine (198)
  3. Hematologic Malignancies, Division of (198)
  4. Lymphoma (198)
  5. Survivorship Research (105)
  6. Population Sciences Research Program (104)

More Groups

People
  1. Andrew Zelenetz (137)
  2. Paul Hamlin (108)
  3. Alison Moskowitz (106)
  4. Ariela Noy (106)
  5. Maria Palomba (101)
  6. Steven Horwitz (99)

More People

Years
  1. 2025 (7)
  2. 2024 (34)
  3. 2023 (32)
  4. 2022 (12)
  5. 2021 (24)
  6. 2020 (17)

More Years

Publications
  1. Blood (84)
  2. Hematological Oncology (19)
  3. Journal of Clinical Oncology (13)
  4. Blood Advances (11)
  5. Haematologica (9)
  6. Leukemia and Lymphoma (8)

More Publications

Publishers
  1. American Society of Hematology (96)
  2. Wiley Blackwell (19)
  3. American Society of Clinical Oncology (13)
  4. Nature Publishing Group (10)
  5. Ferrata Storti Foundation (9)
  6. Taylor & Francis Group (9)

More Publishers

Results (198)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma
    Correspondence

    Gurumurthi, A.; Bantilan, K. S.; Hamlin, P. A.; Kumar, A.; Matasar, M.; Zhu, M.; Joseph, A.; Castro, A.; Biggar, E.; Salles, G.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
    Research Letter

    Lue, J. K.; Luttwak, E.; Rivas-Delgado, A.; Irawan, H.; Boardman, A.; Caron, P. C.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • What is high-risk mantle cell lymphoma, and how should we treat it?
    Journal Article

    Epstein-Peterson, Z.; Kumar, A.
    Targeted Therapies in Oncology (2024)

    Fulltext@MSK | Save
  • Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: A phase 1b/2a trial
    Journal Article

    Horwitz, S. M.; Nirmal, A. J.; Rahman, J.; Xu, R.; Drill, E.; Galasso, N.; Ganesan, N.; Davey, T.; Hancock, H.; Perez, L.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
    Research Letter

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Pak, T.; Chang, T.; Dao, P.; Moskowitz, A. J.; Stuver, R. N.; Ghione, P.; Galasso, N.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma
    Meeting Abstract

    Wang, Y.; Larson, M. C.; Kumar, A.; Hill, B. T.; Bond, D. A.; Kahl, B. S.; Danilov, A. V.; Merryman, R.; Grover, N. S.; Tun, A. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Dismantling relapsed/refractory mantle cell lymphoma
    Review

    Ryan, C. E.; Kumar, A.
    Blood Reviews (2024)

    Fulltext@MSK | Save
  • MYC overexpression: Adding another piece to the puzzle of high-risk mantle cell lymphoma
    Editorial

    Kumar, A.
    Haematologica (2024)

    Fulltext@MSK | Save
  • Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
    Journal Article

    Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Journal Article

    Grieve, C.; Joseph, A.; Drullinsky, P.; Zelenetz, A. D.; Hamlin, P.; Kumar, A.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save